Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial

BACKGROUND: Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitor (Empagliflozin) is an effective drug in controlling blood glucose through predominantly glycosuria. Glycosuria increases the risk of genitourinary infections in diabetes. This study was aimed to establish the safety and efficacy of Empagl...

Descripción completa

Detalles Bibliográficos
Autores principales: Aamir, Azizul Hasan, Raja, Umar Yousaf, Qureshi, Faisal Masood, Asghar, Ali, Mahar, Saeed Ahmed, Ahmed, Ibrar, Ghaffar, Tahir, Zafar, Jamal, Hasan, Mohammad Imtiaz, Riaz, Amna, Raza, Syed Abbas, Khosa, Irshad Ahmed, Khan, Jahanzeb, Baqar, Jaffer Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703399/
https://www.ncbi.nlm.nih.gov/pubmed/36443769
http://dx.doi.org/10.1186/s12902-022-01213-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703399/
https://www.ncbi.nlm.nih.gov/pubmed/36443769
http://dx.doi.org/10.1186/s12902-022-01213-1

Ejemplares similares